Free Trial
→ Elon Musk’s $1 Quadrillion AI IPO (From Brownstone Research) (Ad)tc pixel Free GMTX Stock Alerts

Gemini Therapeutics (GMTX) Financials

Gemini Therapeutics logo
$67.64 +0.73 (+1.09%)
As of 05/4/2026
Compare
Annual Income Statements for Gemini Therapeutics

Annual Income Statements for Gemini Therapeutics

This table shows Gemini Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -41 -36 -47 -76 -109 -212
Consolidated Net Income / (Loss)		 -41 -36 -47 -76 -109 -212
Net Income / (Loss) Continuing Operations		 -41 -36 -47 -76 -109 -212
Total Pre-Tax Income 		-41 -36 -47 -76 -109 -212
Total Operating Income		 -34 -31 -47 -91 -130 -236
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 34 31 47 91 130 236
Selling, General & Admin Expense		 5.87 5.76 14 22 33 65
Research & Development Expense		 28 25 33 69 97 171
Total Other Income / (Expense), net		 -6.80 -5.04 0.65 15 21 24
Interest Expense		 6.83 - - 0.00 0.57 3.61
Interest & Investment Income		 0.04 0.01 0.71 15 21 28
Other Income / (Expense), net		 -0.01 -5.05 -0.06 -0.00 -0.00 0.05
Income Tax Expense		 - - 0.00 0.10 0.36 0.36
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - - - 0.00 -0.32 -0.68
Basic Earnings per Share		 ($2.70) ($40.95) ($45.05) ($3.42) ($3.96) ($6.01)
Weighted Average Basic Shares Outstanding		 15.12M 878.41K 1.04M 22.32M 27.61M 35.30M
Diluted Earnings per Share		 ($2.70) ($40.95) ($45.05) ($3.42) ($3.96) ($6.01)
Weighted Average Diluted Shares Outstanding		 15.12M 878.41K 1.04M 22.32M 27.61M 35.30M
Weighted Average Basic & Diluted Shares Outstanding		 15.12M 40.36M 19.00M 24.68M 34.57M 38.16M

Quarterly Income Statements for Gemini Therapeutics

This table shows Gemini Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -16 -14 -24 0.00 -26 -27 -29 0.00 -55 -62 -94
Consolidated Net Income / (Loss)		 -16 -14 -24 -27 -26 -27 -29 -34 -55 -62 -61
Net Income / (Loss) Continuing Operations		 -16 -14 -24 -27 -26 -27 -29 -34 -55 -62 -61
Total Pre-Tax Income 		-16 -14 -24 -27 -26 -26 -29 -34 -55 -62 -60
Total Operating Income		 -17 -19 -30 -31 -31 -33 -35 -40 -61 -68 -67
Total Operating Expenses		 17 19 30 31 31 33 35 40 61 68 67
Selling, General & Admin Expense		 5.23 4.54 7.15 7.76 7.37 8.17 9.75 12 15 17 21
Research & Development Expense		 12 14 23 24 23 25 25 28 46 50 46
Total Other Income / (Expense), net		 1.41 4.86 6.17 4.52 4.56 6.37 5.27 5.98 6.22 5.48 6.53
Interest Expense		 - - - - 0.00 0.00 - 0.90 0.91 0.92 0.88
Interest & Investment Income		 2.91 4.84 4.68 4.52 4.57 6.36 5.84 6.88 7.06 6.41 7.41
Other Income / (Expense), net		 -1.51 0.01 1.49 -0.00 -0.01 0.01 - -0.00 0.07 -0.02 -0.00
Income Tax Expense		 0.02 0.02 0.03 0.01 0.06 0.11 0.18 0.12 0.05 0.10 0.09
Basic Earnings per Share		 ($0.74) ($0.58) ($1.06) ($1.09) ($1.03) ($0.89) ($1.07) ($1.02) ($1.58) ($1.77) ($1.64)
Weighted Average Basic Shares Outstanding		 21.48M 24.32M 22.32M 24.81M 25.65M 29.94M 27.61M 33.32M 35.02M 35.18M 35.30M
Diluted Earnings per Share		 ($0.74) ($0.58) ($1.06) ($1.09) ($1.03) ($0.89) ($1.07) ($1.02) ($1.58) ($1.77) ($1.64)
Weighted Average Diluted Shares Outstanding		 21.48M 24.32M 22.32M 24.81M 25.65M 29.94M 27.61M 33.32M 35.02M 35.18M 35.30M
Weighted Average Basic & Diluted Shares Outstanding		 22.88M 24.14M 24.68M 24.72M 29.73M 29.76M 34.57M 34.63M 34.77M 37.75M 38.16M

Annual Cash Flow Statements for Gemini Therapeutics

This table details how cash moves in and out of Gemini Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.45 62 107 166 -168 -101
Net Cash From Operating Activities		 -33 -28 -42 -73 -94 -180
Net Cash From Continuing Operating Activities		 -34 -28 -42 -73 -94 -180
Net Income / (Loss) Continuing Operations		 -41 -36 -47 -76 -109 -212
Consolidated Net Income / (Loss)		 -41 -36 -47 -76 -109 -212
Depreciation Expense		 0.32 0.03 0.09 0.10 0.16 0.28
Amortization Expense		 - - - 0.00 -5.30 -8.52
Non-Cash Adjustments To Reconcile Net Income		 7.47 6.98 2.04 5.94 22 41
Changes in Operating Assets and Liabilities, net		 -0.73 1.43 2.44 -3.07 -1.43 -0.97
Net Cash From Investing Activities		 -0.02 -0.07 -0.15 -0.09 -292 -394
Net Cash From Continuing Investing Activities		 -0.02 -0.07 -0.15 -0.09 -292 -394
Purchase of Property, Plant & Equipment		 -0.02 -0.07 -0.15 -0.09 -0.51 -0.93
Purchase of Investments		 - - - 0.00 -387 -850
Sale and/or Maturity of Investments		 - - - 0.00 95 456
Net Cash From Financing Activities		 34 90 149 239 218 473
Net Cash From Continuing Financing Activities		 34 90 149 239 218 473
Repayment of Debt		 0.00 0.00 0.00 0.00 -1.39 0.00
Issuance of Debt		 14 0.00 0.00 0.00 29 0.00
Issuance of Common Equity		 20 0.00 54 199 188 451
Other Financing Activities, net		 0.16 0.07 95 40 2.98 23
Cash Interest Paid		 0.35 0.00 0.00 0.00 0.20 2.80

Quarterly Cash Flow Statements for Gemini Therapeutics

This table details how cash moves in and out of Gemini Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Change in Cash & Equivalents		 141 -7.06 -10 -18 -62 -88 -0.20 -70 4.66 13 -50
Net Cash From Operating Activities		 -13 -7.48 -18 -34 -15 -17 -28 -41 -48 -48 -43
Net Cash From Continuing Operating Activities		 -13 -7.48 -18 -34 -15 -17 -28 -41 -48 -48 -43
Net Income / (Loss) Continuing Operations		 -16 -14 -24 -27 -26 -27 -29 -34 -55 -62 -61
Consolidated Net Income / (Loss)		 -16 -14 -24 -27 -26 -27 -29 -34 -55 -62 -61
Depreciation Expense		 0.03 0.03 0.03 0.03 0.11 0.01 0.01 0.02 0.09 0.09 0.09
Amortization Expense		 - - - 0.00 - -2.50 -2.21 -2.53 -2.62 -1.74 -1.63
Non-Cash Adjustments To Reconcile Net Income		 2.60 1.70 0.61 7.89 12 10 -4.72 7.41 9.70 9.93 14
Changes in Operating Assets and Liabilities, net		 0.60 4.92 5.15 -15 -0.97 1.54 8.80 -12 0.17 6.24 4.81
Net Cash From Investing Activities		 -0.01 -0.05 -0.00 -0.07 -220 -71 -1.43 -273 52 50 -223
Net Cash From Continuing Investing Activities		 -0.01 -0.05 -0.00 -0.07 -220 -71 -1.43 -273 52 50 -223
Purchase of Property, Plant & Equipment		 -0.01 -0.05 -0.00 -0.07 0.00 0.01 -0.45 -0.85 -0.04 -0.03 -0.02
Purchase of Investments		 - - - 0.00 - -94 -73 -347 -59 -85 -358
Sale and/or Maturity of Investments		 - - - 0.00 - - 72 75 110 135 135
Net Cash From Financing Activities		 154 0.46 7.76 16 173 0.43 29 244 0.89 12 217
Net Cash From Continuing Financing Activities		 154 0.46 7.76 16 173 0.43 29 244 0.89 12 217
Issuance of Common Equity		 181 -0.16 -31 15 173 0.03 - 234 - 10 206
Other Financing Activities, net		 -27 0.62 38 0.81 0.57 0.40 1.20 9.96 0.89 1.53 10
Cash Interest Paid		 - - - 0.00 - - - 0.70 0.71 0.71 0.68

Annual Balance Sheets for Gemini Therapeutics

This table presents Gemini Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 8.32 92 200 368 497 807
Total Current Assets		 5.07 90 198 366 494 804
Cash & Equivalents		 4.50 88 195 360 192 91
Short-Term Investments		 - - - 0.00 297 700
Prepaid Expenses		 0.56 2.45 3.88 5.28 3.73 13
Plant, Property, & Equipment, net		 0.29 0.11 0.17 0.17 0.75 1.16
Total Noncurrent Assets		 2.96 1.82 1.55 2.16 2.41 1.82
Other Noncurrent Operating Assets		 2.96 1.82 1.55 2.16 2.41 1.82
Total Liabilities & Shareholders' Equity		 8.32 92 200 368 497 807
Total Liabilities		 30 15 24 23 53 67
Total Current Liabilities		 25 13 23 21 23 37
Accounts Payable		 2.38 2.56 16 13 7.95 9.02
Accrued Expenses		 5.81 4.10 6.11 8.15 15 27
Other Current Liabilities		 - 6.77 0.31 0.67 0.13 0.61
Total Noncurrent Liabilities		 5.30 1.33 1.03 1.44 30 30
Long-Term Debt		 4.95 - - 0.00 28 29
Other Noncurrent Operating Liabilities		 0.35 1.33 1.03 1.44 1.55 1.25
Commitments & Contingencies		 - 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -22 78 177 345 444 740
Total Preferred & Common Equity		 -22 -64 177 345 444 740
Preferred Stock		 0.00 142 - 0.00 0.00 0.00
Total Common Equity		 -22 -64 177 345 444 740
Common Stock		 91 1.19 289 534 741 1,249
Retained Earnings		 -113 -65 -112 -189 -298 -510
Accumulated Other Comprehensive Income / (Loss)		 - - - 0.00 0.29 0.97

Quarterly Balance Sheets for Gemini Therapeutics

This table presents Gemini Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets		 106 244 384 376 354 510 495 709 665 630
Total Current Assets		 105 242 382 374 352 508 493 706 662 627
Cash & Equivalents		 102 236 378 371 343 281 193 123 127 141
Short-Term Investments		 - - - - - 220 295 572 523 475
Prepaid Expenses		 2.93 5.72 4.13 3.72 9.33 7.30 5.79 11 12 11
Plant, Property, & Equipment, net		 0.00 0.18 0.16 0.18 0.21 0.10 0.08 1.37 1.29 1.23
Total Noncurrent Assets		 1.37 1.46 2.28 2.05 2.02 1.88 1.91 2.30 2.18 2.06
Other Noncurrent Operating Assets		 1.37 1.46 2.28 2.05 2.02 1.88 1.91 2.30 2.18 2.06
Total Liabilities & Shareholders' Equity		 106 244 384 376 354 510 495 709 665 630
Total Liabilities		 1.46 11 13 18 16 21 27 49 51 57
Total Current Liabilities		 1.46 9.98 9.68 14 15 20 25 19 21 27
Accounts Payable		 1.14 5.64 5.21 8.50 5.27 4.75 3.55 6.70 6.35 7.27
Accrued Expenses		 0.33 4.03 4.15 5.57 8.82 15 22 12 14 19
Other Current Liabilities		 - 0.31 0.32 0.35 0.77 0.76 0.08 0.48 0.63 0.66
Total Noncurrent Liabilities		 0.00 0.95 3.27 3.11 1.26 1.08 1.71 30 30 30
Long-Term Debt		 0.00 - - - - - - 29 29 29
Other Noncurrent Operating Liabilities		 0.00 0.95 3.27 3.11 1.26 1.08 1.71 1.63 1.55 1.37
Commitments & Contingencies		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 105 233 371 359 338 489 468 660 614 573
Total Preferred & Common Equity		 105 233 371 359 338 489 468 660 614 573
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Common Equity		 105 233 371 359 338 489 468 660 614 573
Common Stock		 315 368 522 524 554 731 736 992 1,001 1,022
Retained Earnings		 -210 -135 -151 -165 -216 -242 -269 -332 -387 -450
Accumulated Other Comprehensive Income / (Loss)		 - - - - - -0.06 0.74 0.54 0.27 0.72

Annual Metrics And Ratios for Gemini Therapeutics

This table displays calculated financial ratios and metrics derived from Gemini Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -6.60% -31.98% -91.85% -48.16% -81.07%
EBIT Growth		 0.00% -5.68% -32.11% -91.70% -42.35% -81.91%
NOPAT Growth		 0.00% 9.13% -53.48% -91.94% -42.35% -81.95%
Net Income Growth		 0.00% 11.92% -30.19% -63.22% -43.08% -94.03%
EPS Growth		 0.00% 11.92% -10.01% 92.41% -15.79% -51.77%
Operating Cash Flow Growth		 0.00% 15.82% -53.45% -73.87% -27.86% -92.06%
Free Cash Flow Firm Growth		 0.00% 0.00% -60.09% -159.87% -32.40% -82.78%
Invested Capital Growth		 0.00% -119.79% -73.47% 15.27% -17.76% -23.34%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 40.87% -129.18% -22.29% -9.45% -14.92%
EBIT Q/Q Growth		 0.00% 41.08% -130.60% -22.26% -5.12% -15.90%
NOPAT Q/Q Growth		 0.00% 49.34% -291.48% -19.22% -3.87% -15.92%
Net Income Q/Q Growth		 0.00% 47.38% -167.49% -19.25% -5.68% -17.16%
EPS Q/Q Growth		 0.00% 47.38% -147.12% -29.55% -14.45% -21.41%
Operating Cash Flow Q/Q Growth		 0.00% 50.73% -222.81% -12.45% -11.62% -9.55%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -84.47% -70.15% -10.69% -8.55%
Invested Capital Q/Q Growth		 0.00% -305.43% -736.43% -31.94% 7.38% -63.22%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.13% 100.33% 100.17%
Interest Burden Percent		 119.94% 99.96% 98.51% 83.76% 84.03% 89.76%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 186.80% -128.94% -36.84% -29.30% -27.73% -35.86%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 186.80% 198.90% -16.28% -29.30% -27.73% -35.86%
Return on Equity Simple (ROE_SIMPLE)		 186.80% 56.02% -26.52% -22.15% -24.65% 0.00%
Net Operating Profit after Tax (NOPAT)		 -24 -22 -33 -64 -91 -165
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 99.25% -40.38% -9.62% -4.56% -4.51% -7.68%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -18.48% -19.24% -21.48%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -34 -36 -48 -91 -130 -236
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -34 -36 -47 -91 -135 -244
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.16 4.04 4.25 4.05
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.16 4.04 4.25 4.05
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 -0.99 0.00 0.00 0.00 0.06 0.04
Long-Term Debt to Equity		 -0.23 0.00 0.00 0.00 0.06 0.04
Financial Leverage		 -0.78 -1.27 -1.11 -1.06 -1.04 -1.03
Leverage Ratio		 -0.38 1.81 1.15 1.09 1.10 1.10
Compound Leverage Factor		 -0.46 1.80 1.13 0.91 0.92 0.99
Debt to Total Capital		 -9,791.86% 0.00% 0.00% 0.00% 6.00% 3.79%
Short-Term Debt to Total Capital		 -7,551.58% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 -2,240.27% 0.00% 0.00% 0.00% 6.00% 3.79%
Preferred Equity to Total Capital		 0.00% 182.68% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 9,891.86% -82.68% 100.00% 100.00% 94.00% 96.21%
Debt to EBITDA		 -0.64 0.00 0.00 0.00 -0.21 -0.12
Net Debt to EBITDA		 -0.51 0.00 0.00 0.00 3.42 3.12
Long-Term Debt to EBITDA		 -0.15 0.00 0.00 0.00 -0.21 -0.12
Debt to NOPAT		 -0.91 0.00 0.00 0.00 -0.31 -0.18
Net Debt to NOPAT		 -0.72 0.00 0.00 0.00 5.08 4.61
Long-Term Debt to NOPAT		 -0.21 0.00 0.00 0.00 -0.31 -0.18
Altman Z-Score		 -31.95 3.83 0.22 36.16 20.72 26.12
Noncontrolling Interest Sharing Ratio		 0.00% 254.26% 55.79% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 0.20 6.74 8.79 17.06 21.17 21.94
Quick Ratio		 0.18 6.56 8.62 16.81 21.01 21.59
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -16 -26 -67 -88 -161
Operating Cash Flow to CapEx		 -148,672.73% -40,491.18% -27,981.46% -82,541.57% -18,599.21% -19,334.73%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 -154.01 -44.64
Operating Cash Flow to Interest Expense		 -4.79 0.00 0.00 0.00 -164.21 -50.01
Operating Cash Flow Less CapEx to Interest Expense		 -4.79 0.00 0.00 0.00 -165.09 -50.27
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -4.72 -10 -18 -15 -18 -22
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -5.66 -7.63 2.75 -2.71 -4.20
Enterprise Value (EV)		 188 179 -166 1,034 1,425 2,236
Market Capitalization		 171 125 29 1,394 1,887 2,998
Book Value per Share		 ($1.41) ($1.49) $4.08 $14.30 $14.91 $19.60
Tangible Book Value per Share		 ($1.41) ($1.49) $4.08 $14.30 $14.91 $19.60
Total Capital		 -0.22 78 177 345 472 769
Total Debt		 22 0.00 0.00 0.00 28 29
Total Long-Term Debt		 4.95 0.00 0.00 0.00 28 29
Net Debt		 17 -88 -195 -360 -462 -762
Capital Expenditures (CapEx)		 0.02 0.07 0.15 0.09 0.51 0.93
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.63 -11 -19 -16 -20 -24
Debt-free Net Working Capital (DFNWC)		 -3.12 77 176 344 470 767
Net Working Capital (NWC)		 -20 77 176 344 470 767
Net Nonoperating Expense (NNE)		 17 14 14 13 19 47
Net Nonoperating Obligations (NNO)		 17 -88 -195 -360 -462 -762
Total Depreciation and Amortization (D&A)		 0.32 0.03 0.09 0.10 -5.15 -8.24
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($53.40) ($45.05) ($3.42) ($3.96) ($6.01)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 1.44M 1.04M 22.32M 27.61M 35.30M
Adjusted Diluted Earnings per Share		 $0.00 ($53.40) ($45.05) ($3.42) ($3.96) ($6.01)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 1.44M 1.04M 22.32M 27.61M 35.30M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($53.40) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 1.35M 19.00M 24.68M 34.57M 38.16M
Normalized Net Operating Profit after Tax (NOPAT)		 -24 -22 -33 -64 -91 -165
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -4.99 0.00 0.00 0.00 -226.78 -65.42
NOPAT to Interest Expense		 -3.49 0.00 0.00 0.00 -158.75 -45.80
EBIT Less CapEx to Interest Expense		 -4.99 0.00 0.00 0.00 -227.67 -65.68
NOPAT Less CapEx to Interest Expense		 -3.49 0.00 0.00 0.00 -159.63 -46.06
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Gemini Therapeutics

This table displays calculated financial ratios and metrics derived from Gemini Therapeutics' official financial filings.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -95.86% -15.40% -142.95% -25.25% -63.52% -86.74% -30.33% -35.05% -103.75% -96.33% -86.44%
EBIT Growth		 -95.67% -15.38% -142.64% -25.23% -63.89% -73.38% -22.41% -26.97% -98.74% -106.15% -93.86%
NOPAT Growth		 -44.22% -80.91% -97.82% -25.22% -78.05% -73.31% -16.28% -26.97% -99.05% -106.04% -93.84%
Net Income Growth		 -66.46% 12.56% -109.70% -18.30% -65.25% -88.35% -24.93% -26.48% -109.65% -134.30% -105.49%
EPS Growth		 92.70% 96.55% 90.20% 9.17% -39.19% -53.45% -0.94% 6.42% -53.40% -98.88% 19.21%
Operating Cash Flow Growth		 -38.39% 22.86% -84.13% 5.26% -20.98% -132.22% -54.94% -23.15% -211.30% -175.32% -57.04%
Free Cash Flow Firm Growth		 59.93% 108.85% -715.80% -19.33% -245.19% -1,446.16% 8.81% -27.03% -202.79% -250.91% -98.77%
Invested Capital Growth		 -654.56% -508.73% 15.27% -27.39% -89.82% -67.74% -17.76% -27.00% 41.64% 30.01% -23.34%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 25.07% -0.60% -49.04% -11.48% 2.17% -14.88% -4.02% -15.52% -50.46% -8.59% 1.23%
EBIT Q/Q Growth		 25.04% -0.59% -48.98% -11.48% 1.90% -6.42% -5.18% -15.63% -53.55% -10.39% 1.10%
NOPAT Q/Q Growth		 31.03% -9.41% -56.74% -5.88% 1.94% -6.50% -5.16% -15.62% -53.73% -10.24% 1.07%
Net Income Q/Q Growth		 30.00% 11.44% -66.97% -14.29% 2.22% -0.94% -10.74% -15.71% -62.09% -12.80% 2.87%
EPS Q/Q Growth		 38.33% 21.62% -82.76% -2.83% 5.50% 13.59% -20.22% 4.67% -54.90% -12.03% 7.34%
Operating Cash Flow Q/Q Growth		 64.12% 41.24% -138.04% -88.80% 54.19% -12.79% -58.82% -50.06% -15.81% 0.25% 9.41%
Free Cash Flow Firm Q/Q Growth		 73.94% 124.51% -2,190.71% 10.63% 24.63% 4.41% -41.62% -24.50% -79.66% -10.78% 19.78%
Invested Capital Q/Q Growth		 -78.95% -81.22% -31.94% 70.22% -166.64% -60.14% 7.38% 67.89% -22.53% -92.07% -63.22%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.15% 100.14% 100.14% 100.02% 100.23% 100.43% 100.60% 100.35% 100.09% 100.16% 100.15%
Interest Burden Percent		 84.55% 74.44% 83.43% 85.64% 85.18% 80.63% 84.75% 85.02% 89.98% 91.89% 90.25%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -27.66% -27.65% -29.30% -28.23% -21.16% -25.03% -27.73% -23.34% -26.36% -34.78% -35.86%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -27.66% -27.65% -29.30% -28.23% -21.16% -25.03% -27.73% -23.34% -26.36% -34.78% -35.86%
Return on Equity Simple (ROE_SIMPLE)		 -17.81% -17.85% 0.00% -23.84% -18.62% -22.11% 0.00% -17.64% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -12 -13 -21 -22 -22 -23 -24 -28 -43 -47 -47
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.58% -0.36% -1.00% -1.70% -1.08% -0.84% -1.28% -1.21% -2.19% -2.78% -2.23%
Return On Investment Capital (ROIC_SIMPLE)		 - - -6.03% - - - -5.12% -4.06% -6.69% -7.87% -6.10%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -19 -19 -28 -31 -31 -33 -35 -40 -61 -68 -67
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -19 -19 -28 -31 -31 -35 -37 -42 -64 -69 -69
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.37 2.99 4.04 4.55 2.28 3.12 4.25 2.60 2.99 4.01 4.05
Price to Tangible Book Value (P/TBV)		 2.37 2.99 4.04 4.55 2.28 3.12 4.25 2.60 2.99 4.01 4.05
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.06 0.04 0.05 0.05 0.04
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.06 0.04 0.05 0.05 0.04
Financial Leverage		 -1.01 -1.02 -1.06 -1.01 -1.02 -1.04 -1.04 -1.01 -1.02 -1.03 -1.03
Leverage Ratio		 1.04 1.04 1.09 1.05 1.04 1.05 1.10 1.07 1.07 1.08 1.10
Compound Leverage Factor		 0.88 0.77 0.91 0.90 0.89 0.85 0.93 0.91 0.96 0.99 0.99
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6.00% 4.14% 4.47% 4.81% 3.79%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6.00% 4.14% 4.47% 4.81% 3.79%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 94.00% 95.86% 95.53% 95.19% 96.21%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -0.21 -0.20 -0.16 -0.14 -0.12
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 3.42 4.57 3.48 2.76 3.12
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -0.21 -0.20 -0.16 -0.14 -0.12
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -0.31 -0.29 -0.24 -0.20 -0.18
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 5.08 6.89 5.26 4.12 4.61
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -0.31 -0.29 -0.24 -0.20 -0.18
Altman Z-Score		 41.16 37.17 36.72 57.22 31.54 32.39 21.35 21.37 21.66 23.94 26.81
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 39.42 25.96 17.06 23.70 25.02 19.36 21.17 37.65 32.11 23.45 21.94
Quick Ratio		 39.00 25.70 16.81 23.07 24.66 19.13 21.01 37.07 31.54 23.03 21.59
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -4.60 1.13 -24 -21 -16 -15 -21 -27 -48 -53 -43
Operating Cash Flow to CapEx		 -106,033.33% -16,613.33% -593,200.00% -50,147.76% 0.00% 0.00% -6,140.98% -4,862.04% -133,105.56% -183,842.31% -216,500.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -29.81 -52.78 -58.03 -48.34
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -46.13 -52.66 -52.13 -49.04
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -47.08 -52.70 -52.15 -49.06
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -6.38 -12 -15 -4.54 -12 -19 -18 -5.77 -7.07 -14 -22
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -7.53 -14 2.75 -0.98 -5.73 -7.84 -2.71 -1.23 5.05 5.82 -4.20
Enterprise Value (EV)		 501 704 1,034 1,194 613 973 1,425 1,050 1,213 1,710 2,236
Market Capitalization		 879 1,075 1,394 1,537 1,114 1,461 1,887 1,716 1,834 2,297 2,998
Book Value per Share		 $18.75 $15.69 $14.30 $13.70 $19.77 $15.74 $14.91 $19.10 $17.73 $16.49 $19.60
Tangible Book Value per Share		 $18.75 $15.69 $14.30 $13.70 $19.77 $15.74 $14.91 $19.10 $17.73 $16.49 $19.60
Total Capital		 371 359 345 338 489 468 472 689 643 602 769
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 28 29 29 29 29
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 28 29 29 29 29
Net Debt		 -378 -371 -360 -343 -501 -487 -462 -666 -621 -587 -762
Capital Expenditures (CapEx)		 0.01 0.05 0.00 0.07 -0.00 -0.01 0.45 0.85 0.04 0.03 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.55 -11 -16 -5.52 -13 -20 -20 -7.80 -8.99 -15 -24
Debt-free Net Working Capital (DFNWC)		 372 360 344 337 488 468 470 687 641 600 767
Net Working Capital (NWC)		 372 360 344 337 488 468 470 687 641 600 767
Net Nonoperating Expense (NNE)		 3.82 0.85 2.78 4.93 4.76 3.60 5.27 6.12 12 15 14
Net Nonoperating Obligations (NNO)		 -378 -371 -360 -343 -501 -487 -462 -666 -621 -587 -762
Total Depreciation and Amortization (D&A)		 0.03 0.03 0.03 0.03 0.11 -2.49 -2.20 -2.51 -2.54 -1.65 -1.54
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.74) ($0.58) ($1.06) ($1.09) ($1.03) ($0.89) ($1.07) ($1.02) ($1.58) ($1.77) ($1.64)
Adjusted Weighted Average Basic Shares Outstanding		 21.48M 24.32M 22.32M 24.81M 25.65M 29.94M 27.61M 33.32M 35.02M 35.18M 35.30M
Adjusted Diluted Earnings per Share		 ($0.74) ($0.58) ($1.06) ($1.09) ($1.03) ($0.89) ($1.07) ($1.02) ($1.58) ($1.77) ($1.64)
Adjusted Weighted Average Diluted Shares Outstanding		 21.48M 24.32M 22.32M 24.81M 25.65M 29.94M 27.61M 33.32M 35.02M 35.18M 35.30M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($1.06) $0.00 $0.00 $0.00 ($1.07) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 22.88M 24.14M 24.68M 24.72M 29.73M 29.76M 34.57M 34.63M 34.77M 37.75M 38.16M
Normalized Net Operating Profit after Tax (NOPAT)		 -12 -13 -21 -22 -22 -23 -24 -28 -43 -47 -47
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -44.54 -67.41 -73.84 -75.85
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -31.17 -47.24 -51.68 -53.09
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -45.48 -67.45 -73.87 -75.87
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -32.12 -47.28 -51.70 -53.11
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Disc Medicine (NASDAQ: IRON) has shown a persistent cash burn in the latest four quarters, with no material revenue yet and the company funding its operations mainly through equity financing. The balance sheet remains heavily equity-funded, and cash runway appears closely tied to ongoing share issuances. Here is a concise, data-driven look at the trends from the last four years using the provided quarterly statements.

  • Equity financing inflows remain a key liquidity source. The company secured sizable common equity issuances in recent quarters, notably a large issuance in Q4 2025 (approximately $206.3 million) which contributed to a net financing cash flow around $216.7 million. Comparable—but smaller—equity inflows occurred in Q3 2025.
  • Strong equity base visible on the balance sheet. Total Common Equity sits in the high hundreds of millions across 2025 quarters (with values ranging around the $570–660 million level), indicating substantial cash raised through equity financing and a large capital base relative to current earnings.
  • Cash on hand provides near-term liquidity for R&D and operations. Cash & equivalents balance near mid-2025 (e.g., about $140.7 million in Q3 2025) suggests a meaningful liquidity runway to support ongoing development activities.
  • Interest expense remains modest, implying a light debt burden. Interest expense in several quarters runs under $1 million, indicating the company has limited leverage and relatively low ongoing interest obligations compared with net losses.
  • No revenue in the latest periods. Total Revenue is reported as 0 in Q3 2025 and Q4 2025, with similar lack of top-line activity in other recent quarters, highlighting the company’s development-stage status.
  • R&D and SG&A remain the primary operating costs. In Q4 2025, SG&A is about $20.7 million and R&D about $46.2 million, contributing to total operating expenses of about $66.97 million—typical for biotech firms investing in pipeline development and clinical work.
  • Depreciation, amortization, and non-cash items are sizable but non-cash in nature. Depreciation and amortization add back to cash flow in some quarters (e.g., $89k depreciation in Q4 2025; amortization can be negative in some periods), while non-cash adjustments can be meaningful in certain quarters.
  • Continued net losses and negative earnings per share. Net income (loss) continues to be negative across recent quarters (e.g., Q4 2025 net income of about -$60.5 million; Q3 2025 around -$62.3 million; Q1 2025 around -$34.1 million; Q4 2024 around -$29.5 million). Corresponding basic/diluted EPS are also negative (for example, Q4 2025 EPS around -$1.64).
  • Operating cash flow remains negative, signaling ongoing cash burn from core operations. Net cash from continuing operating activities is negative in the recent quarters (e.g., around -$43.3 million in Q4 2025 and about -$47.8 million in Q3 2025), underscoring a continuing need for external funding.
  • Accumulated deficit remains large, with Retained Earnings deeply negative. Retained earnings are negative across the period (e.g., approximately -$449.7 million by Q4 2025), reflecting sustained losses and ongoing financing needs.
05/05/26 06:32 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Gemini Therapeutics' Financials

When does Gemini Therapeutics' fiscal year end?

According to the most recent income statement we have on file, Gemini Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

How has Gemini Therapeutics' net income changed over the last 5 years?

Gemini Therapeutics' net income appears to be on an upward trend, with a most recent value of -$212.18 million in 2025, rising from -$40.84 million in 2020. The previous period was -$109.36 million in 2024.

What is Gemini Therapeutics' operating income?
Gemini Therapeutics' total operating income in 2025 was -$236.02 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $236.02 million
How has Gemini Therapeutics' revenue changed over the last 5 years?

Over the last 5 years, Gemini Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

How much debt does Gemini Therapeutics have?

Gemini Therapeutics' total liabilities were at $67.05 million at the end of 2025, a 26.1% increase from 2024, and a 122.2% increase since 2020.

How much cash does Gemini Therapeutics have?

In the past 5 years, Gemini Therapeutics' cash and equivalents has ranged from $4.50 million in 2020 to $360.38 million in 2023, and is currently $91.15 million as of their latest financial filing in 2025.

How has Gemini Therapeutics' book value per share changed over the last 5 years?

Over the last 5 years, Gemini Therapeutics' book value per share changed from -1.41 in 2020 to 19.60 in 2025, a change of -1,492.7%.


Related Companies

Financial statements for NASDAQ:GMTX last updated on 2/27/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel